Sort by
Keyphrases
Chemotherapy
79%
Overall Survival
71%
Colorectal Cancer
63%
Chemotherapy-induced Peripheral Neuropathy
62%
Oncology Patients
56%
Neoadjuvant
55%
Neoadjuvant Therapy
54%
FOLFIRINOX
51%
Resectable Pancreatic Cancer
51%
Oncologic
51%
Metastatic Esophageal Cancer
51%
Tiragolumab
51%
Interleukin-8
41%
Israel
37%
Retrospective Analysis
37%
BRCA mutation
34%
Progression-free Survival
34%
Cannabis
33%
Oxaliplatin
32%
Improved Outcomes
31%
Protective Effect
29%
Chemoradiotherapy
29%
Disease-free Survival
29%
Confidence Interval
29%
Cancer Patients
29%
Postoperative Complications
29%
Complete Response
29%
Locally Advanced Unresectable
28%
Pancreatic Neuroendocrine Tumors (pNETs)
28%
Unresectable Esophageal Cancer
28%
5-year Survival
28%
Borderline Resectable Pancreatic Cancer
27%
Tumor
26%
Prospective Randomized Trial
25%
Paclitaxel
25%
Bone Loss
25%
Nonfunctional Pancreatic Neuroendocrine Tumor
25%
Type 1 Diabetes Mellitus (T1DM)
25%
68Ga-FAPI
25%
Dysglycemia
25%
Postmenopausal Women
25%
Activating mutation
25%
Zoledronic Acid
25%
Long-term Response
25%
Thyroid Cancer
25%
Oxaliplatin-induced Neuropathy
25%
Metastatic Gastric Cancer
25%
Lymph Node Ratio
25%
Advanced Ovarian Cancer
25%
Locally Advanced Rectal Cancer
25%
Medicine and Dentistry
Overall Survival
100%
Diseases
89%
Rectum Cancer
77%
Neoplasm
57%
Pancreas Cancer
54%
Neoadjuvant Therapy
53%
Krukenberg Tumor
51%
Pancreas Islet Cell Tumor
51%
Lymph Node
35%
Retrospective Study
35%
Disease Free Survival
34%
Biological Marker
34%
Progression Free Survival
32%
BRCA Mutation
31%
Chemoradiotherapy
29%
Postoperative Complication
29%
Colon Carcinoma
27%
Cross Sectional Study
25%
Osteolysis
25%
COVID-19
25%
Diabetes Mellitus
25%
Dysglycemia
25%
Phase II Trials
25%
Stomach Adenocarcinoma
25%
Zoledronic Acid
25%
Clinical Trial
25%
Paclitaxel
25%
Breast Cancer
25%
Thyroid Cancer
25%
Doxorubicin
25%
Tomography
25%
Postmenopause
25%
Gallium 68
25%
Carboplatin
25%
Letrozole
25%
Tamoxifen
25%
Vemurafenib
25%
Telemedicine
25%
Fluorodeoxyglucose F 18
25%
Esophageal Cancer
25%
Intraperitoneal Chemotherapy
25%
Lymphocytopenia
25%
Pancreas Fistula
25%
Peritoneum Metastasis
25%
Pancreaticoduodenectomy
25%
Pancreas Adenocarcinoma
25%
Treatment Response
25%
Radiation Therapy
25%
Polyethylene Terephthalate
25%
Magnetic Resonance Imaging
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
76%
Overall Survival
64%
Ovary Carcinoma
51%
Tiragolumab
51%
Neoplasm
45%
Diseases
44%
Chemotherapy-Induced Peripheral Neuropathy
36%
Malignant Neoplasm
32%
Oxaliplatin
29%
Postoperative Complication
29%
Retrospective Study
28%
Pancreas Cancer
28%
Diabetes Mellitus
27%
Colon Carcinoma
27%
Paclitaxel
25%
Chemoradiation Therapy
25%
Pancreas Islet Cell Tumor
25%
Oxaliplatin-Induced Peripheral Neuropathy
25%
Rectum Cancer
25%
Zoledronic Acid
25%
Irritable Colon
25%
Thyroid Cancer
25%
Phase II Trials
25%
Tamoxifen
25%
Doxorubicin
25%
Posttraumatic Stress Disorder
25%
Dysglycemia
25%
Vemurafenib
25%
Carboplatin
25%
Letrozole
25%
Breast Cancer
25%
Cannabis
25%
Pancreas Fistula
25%
Peritoneum Metastasis
25%
Pancreas Adenocarcinoma
25%
Intraperitoneal Chemotherapy
25%
Comorbidity
25%
Adenocarcinoma
25%
Lenvatinib
25%
Pembrolizumab
25%
Noma
25%
Atezolizumab
25%
Progression Free Survival
20%
Impaired Glucose Tolerance
17%
Disease Free Survival
17%
Prevalence
14%
Carcinoma
13%
Neuropathy
12%
Side Effect
10%
Taxane
10%